Jump to content

Main Page: Difference between revisions

From Neoplasm
Newer edit →
VisualWikitext
No edit summary
 
No edit summary
Line 1: Line 1:
<strong>MediaWiki has been installed.</strong>
{{DISPLAYTITLE:<span style="display: none"></span>}}
__NOTOC__
<!--Hides title of Main Page-->
<div style="text-align:center">
<h1>'''HemOnc.org - A Human-Curated Hematology/Oncology Reference'''</h1>
</div>


Consult the [https://www.mediawiki.org/wiki/Special:MyLanguage/Help:Contents User's Guide] for information on using the wiki software.
<div style="text-align:center"><big>HemOnc.org is the largest freely available medical wiki of [[:Category:Intervention_index|interventions]], [[:Category:Regimen_index|regimens]], and [[:Category:General_reference_pages|general information]] relevant to the fields of hematology and oncology. Any healthcare professional can [[How to contribute|sign up to contribute]]; the [[Eligibility criteria|accuracy and completeness of content]] is overseen by the [[Editorial Board]]. If this is your first time visiting, please start with the '''[[Tutorial|the tutorial page]]''', review our '''[[philosophy]]''', or just start exploring!</big></div>


== Getting started ==
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
* [https://www.mediawiki.org/wiki/Special:MyLanguage/Manual:Configuration_settings Configuration settings list]
|-
* [https://www.mediawiki.org/wiki/Special:MyLanguage/Manual:FAQ MediaWiki FAQ]
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|[[Tutorial#Regimens|<span style="color:black;">Regimens</span>]]: 5,549
* [https://lists.wikimedia.org/postorius/lists/mediawiki-announce.lists.wikimedia.org/ MediaWiki release mailing list]
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">[[Guidelines]]: 1,173</span>
* [https://www.mediawiki.org/wiki/Special:MyLanguage/Localisation#Translation_resources Localise MediaWiki for your language]
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">Studies</span>: 7,123
* [https://www.mediawiki.org/wiki/Special:MyLanguage/Manual:Combating_spam Learn how to combat spam on your wiki]
!style="width: 25%; font-size:150%; background-color:#bdbdbd"|<span style="color:black;">References</span>: 10,098
|-
|}
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
|-
|style="width: 20%; font-size:125%; background-color:#08519c"|[[#solidtumors|<span style="color:white;">Solid Tumors</span>]]
|style="width: 20%; font-size:125%; background-color:#cf0001"|[[#malignantheme|<span style="color:white;">Malignant Hematology</span>]]
|style="width: 20%; font-size:125%; background-color:#ba871a"|[[#peds|<span style="color:white;">Pediatrics</span>]]
|style="width: 20%; font-size:125%; background-color:#4a1486"|[[#transplant|<span style="color:white;">Transplant & IEC</span>]]
|style="width: 20%; font-size:125%; background-color:#31a354"|[[#classicalheme|<span style="color:white;">Classical Hematology</span>]]
|-
|}
 
==Links to all main disease pages==
<span id="solidtumors"></span>
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#08519c"| '''Solid Tumors'''
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Breast Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Early breast cancer (EBC)'''
|-
|style="background-color:#eff3ff"|[[Early breast cancer|EBC, NOS]]
|style="background-color:#eff3ff"|[[Early breast cancer, HR-positive|HR-positive EBC]]
|style="background-color:#eff3ff"|[[Early breast cancer, HER2-positive|HER2-positive EBC]]
|style="background-color:#eff3ff"|[[Early breast cancer, HER2-low|HER2-low EBC]]
|-
|style="background-color:#eff3ff"|[[Early breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive EBC]]
|style="background-color:#eff3ff"|[[Early breast cancer, triple negative|Early triple-negative breast cancer (eTNBC)]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Metastatic breast cancer (MBC)'''
|-
|style="background-color:#eff3ff"|[[Metastatic breast cancer|MBC, NOS]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HR-positive|HR-positive MBC]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HER2-positive|HER2-positive MBC]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HER2-low|HER2-low MBC]]
|-
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive MBC]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, triple negative|Metastatic triple-negative breast cancer (mTNBC)]]
|style="background-color:#eff3ff"|[[Breast cancer, CNS metastases|CNS metastases]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Breast cancer with molecular alterations'''
|-
|style="background-color:#eff3ff"|[[Breast cancer, BRCA-mutated|BRCA-mutated Breast cancer]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, PI3K pathway-altered|PI3K pathway-altered Breast cancer]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Dermatologic Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Melanoma'''
|-
|style="background-color:#eff3ff"|[[Melanoma|Melanoma, NOS]]
|style="background-color:#eff3ff"|[[Melanoma,_BRAF-mutated|BRAF-mutated Melanoma]]
|style="background-color:#eff3ff"|[[Melanoma,_KIT-mutated|KIT-mutated Melanoma]]
|style="background-color:#eff3ff"|[[Melanoma,_NRAS-mutated|NRAS-mutated Melanoma]]
|-
|style="background-color:#eff3ff"|[[Uveal melanoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Non-melanoma skin cancer (NMSC)'''
|-
|style="background-color:#eff3ff"|[[Cutaneous basal cell carcinoma | Cutaneous BCC]]
|style="background-color:#eff3ff"|[[Cutaneous squamous cell carcinoma | Cutaneous SCC]]
|style="background-color:#eff3ff"|[[Merkel cell carcinoma|Merkel cell carcinoma (MCC)]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Endocrine Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Other endocrine cancers'''
|-
|style="background-color:#eff3ff"|[[Adrenocortical carcinoma]]
|style="background-color:#eff3ff"|[[Neuroendocrine tumor|Neuroendocrine tumor (NET)]]
|style="background-color:#eff3ff"|[[Neuroendocrine carcinoma|Neuroendocrine carcinoma (NEC)]]
|style="background-color:#eff3ff"|[[Pancreatic NET]]
|-
|style="background-color:#eff3ff"|[[Pheochromocytoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Thyroid cancer without molecular alterations'''
|-
|style="background-color:#eff3ff"|[[Thyroid cancer|Thyroid cancer, NOS]]
|style="background-color:#eff3ff"|[[Thyroid cancer, anaplastic|Anaplastic thyroid cancer (ATC)]]
|style="background-color:#eff3ff"|[[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]]
|style="background-color:#eff3ff"|[[Thyroid cancer, medullary|Medullary thyroid cancer (MTC)]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Thyroid cancer with molecular alterations'''
|-
|style="background-color:#eff3ff"|[[Thyroid_cancer,_BRAF-mutated|BRAF-mutated Thyroid cancer]]
|style="background-color:#eff3ff"|[[Thyroid_cancer,_RET-positive|RET-positive Thyroid cancer]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gastrointestinal Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Upper GI tract'''
|-
|style="width: 25%; background-color:#eff3ff"|[[Esophageal cancer|Esophageal cancer, NOS]]
|style="width: 25%; background-color:#eff3ff"|[[Esophageal adenocarcinoma]]
|style="width: 25%; background-color:#eff3ff"|[[Esophageal squamous cell carcinoma|Esophageal squamous cell carcinoma (ESCC)]]
|style="width: 25%; background-color:#eff3ff"|[[Gastric cancer|Gastric cancer, NOS]]
|-
|style="width: 25%; background-color:#eff3ff"|[[Gastric cancer, HER2-positive|HER2-positive gastric cancer]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Lower GI tract'''
|-
|style="width: 25%; background-color:#eff3ff"|[[Anal cancer]]
|style="width: 25%; background-color:#eff3ff"|[[Appendiceal tumor]]
|style="width: 25%; background-color:#eff3ff"|[[Colon cancer|Colon cancer, NOS]]
|style="width: 25%; background-color:#eff3ff"|[[Colon cancer, RAS wild-type|RAS wild-type colon cancer]]
|-
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer|Colorectal cancer (CRC), NOS]]
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, BRAF-mutated|BRAF-mutated CRC]]
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, HER2-positive|HER2-positive CRC]]
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, MSI-H or dMMR|MSI-H or dMMR CRC]]
|-
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, RAS wild-type|RAS wild-type CRC]]
|style="width: 25%; background-color:#eff3ff"|[[Rectal cancer]]
|style="width: 25%; background-color:#eff3ff"|[[Small bowel adenocarcinoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Hepatobiliary cancer'''
|-
|style="width: 25%; background-color:#eff3ff"|[[Biliary tract cancer]]
|style="width: 25%; background-color:#eff3ff"|[[Cholangiocarcinoma]]
|style="width: 25%; background-color:#eff3ff"|[[Gallbladder cancer]]
|style="width: 25%; background-color:#eff3ff"|[[Hepatocellular carcinoma|Hepatocellular carcinoma (HCC)]]
|-
|style="width: 25%; background-color:#eff3ff"|[[Periampullary adenocarcinoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Pancreatic cancer'''
|-
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic cancer|Pancreatic adenocarcinoma, NOS]]
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic cancer, BRCA-mutated|BRCA-mutated Pancreatic adenocarcinoma]]
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic cancer, NRG1-positive|NRG1-positive Pancreatic adenocarcinoma]]
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic NET]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Genitourinary Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Kidney cancer'''
|-
|style="background-color:#eff3ff"|[[Renal cell carcinoma|Renal cell carcinoma (RCC), NOS]]
|style="background-color:#eff3ff"|[[Clear cell renal cell carcinoma|Clear cell RCC (ccRCC)]]
|style="background-color:#eff3ff"|[[Non-clear cell renal cell carcinoma|Non-clear cell RCC (nccRCC)]]
|style="background-color:#eff3ff"|[[Papillary renal cell carcinoma|Papillary RCC]]
|-
|style="background-color:#eff3ff"|[[Sarcomatoid renal cell carcinoma|Sarcomatoid RCC]]
|style="background-color:#eff3ff"|[[Renal_cell_carcinoma,_VHL-associated|VHL-associated RCC]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Male genital tract'''
|-
|style="background-color:#eff3ff"|[[Penile cancer]]
|style="background-color:#eff3ff"|[[Prostate cancer|Prostate cancer, NOS]]
|style="background-color:#eff3ff"|[[Prostate cancer, HRD-positive]]
|style="background-color:#eff3ff"|[[Testicular cancer]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Urinary tract cancer'''
|-
|style="background-color:#eff3ff"|[[Urothelial carcinoma|Urothelial carcinoma, NOS]]
|style="background-color:#eff3ff"|[[Bladder cancer]]
|style="background-color:#eff3ff"|[[Upper tract urothelial carcinoma|Upper tract urothelial carcinoma (UTUC)]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gynecologic Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Ovarian cancer'''
|-
|style="background-color:#eff3ff"|[[Ovarian cancer|High-grade serous ovarian cancer (HGSOC)]]
|style="background-color:#eff3ff"|[[Low-grade serous ovarian cancer|Low-grade serous ovarian cancer (LGSOC)]]
|style="background-color:#eff3ff"|[[Ovarian cancer, BRCA-mutated]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Other gynecologic cancer'''
|-
|style="background-color:#eff3ff"|[[Cervical cancer]]
|style="background-color:#eff3ff"|[[Endometrial cancer]]
|style="background-color:#eff3ff"|[[Gestational trophoblastic neoplasia]]
|style="background-color:#eff3ff"|[[Vulvar cancer]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Head & Neck Oncology'''
|-
|style="background-color:#eff3ff"|[[Head and neck cancer]]
|style="background-color:#eff3ff"|[[Nasopharyngeal carcinoma|Nasopharyngeal carcinoma (NPC)]]
|style="background-color:#eff3ff"|[[Oropharyngeal_cancer,_HPV-positive|HPV+ Oropharyngeal cancer]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Mesothelioma'''
|-
|colspan="2" style="background-color:#eff3ff"|[[Malignant peritoneal mesothelioma|Malignant peritoneal mesothelioma (MPEM)]]
|colspan="2" style="background-color:#eff3ff"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Neuro-Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Primary central nervous system (CNS) malignancies'''
|-
|style="background-color:#eff3ff"|[[Anaplastic glioma]]
|style="background-color:#eff3ff"|[[Craniopharyngioma]]
|style="background-color:#eff3ff"|[[Diffuse midline glioma]] <span style="color: red"><small>New</small></span>
|style="background-color:#eff3ff"|[[Glioblastoma|Glioblastoma (GBM)]]
|-
|style="background-color:#eff3ff"|[[Low-grade glioma]]
|style="background-color:#eff3ff"|[[Meningioma]]
|style="background-color:#eff3ff"|[[Subependymal giant cell astrocytoma|Subependymal giant cell astrocytoma (SEGA)]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Secondary CNS malignancies'''
|-
|style="background-color:#eff3ff"|[[CNS carcinoma]]
|style="background-color:#eff3ff"|[[CNS leukemia]]
|style="background-color:#eff3ff"|[[CNS lymphoma]]
|style="background-color:#eff3ff"|[[CNS melanoma]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Sarcoma'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Bone sarcoma'''
|-
|style="background-color:#eff3ff"|[[Bone sarcoma|Bone sarcoma, NOS]]
|style="background-color:#eff3ff"|[[Ewing sarcoma]]
|style="background-color:#eff3ff"|[[Giant-cell tumor of bone]]
|style="background-color:#eff3ff"|[[Osteosarcoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Soft tissue sarcoma'''
|-
|style="background-color:#eff3ff"|[[Soft tissue sarcoma|Soft tissue sarcoma (STS), NOS]]
|style="background-color:#eff3ff"|[[Alveolar soft part sarcoma|Alveolar soft part sarcoma (ASPS)]]
|style="background-color:#eff3ff"|[[Dermatofibrosarcoma protuberans]]
|style="background-color:#eff3ff"|[[Desmoid tumor]]
|-
|style="background-color:#eff3ff"|[[Epithelioid sarcoma]]
|style="background-color:#eff3ff"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
|style="background-color:#eff3ff"|[[Inflammatory myofibroblastic tumor|Inflammatory myofibroblastic tumor (IMT)]]
|style="background-color:#eff3ff"|[[Leiomyosarcoma|Leiomyosarcoma (LMS)]]
|-
|style="background-color:#eff3ff"|[[Liposarcoma]]
|style="background-color:#eff3ff"|[[PEComa]]
|style="background-color:#eff3ff"|[[Rhabdomyosarcoma|Rhabdomyosarcoma (RMS)]]
|style="background-color:#eff3ff"|[[Tenosynovial giant cell tumor|Tenosynovial giant cell tumor (TGCT)]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Vascular sarcoma'''
|-
|style="background-color:#eff3ff"|[[Vascular sarcoma|Vascular sarcoma, NOS]]
|style="background-color:#eff3ff"|[[Angiosarcoma]]
|style="background-color:#eff3ff"|[[Kaposi sarcoma|Kaposi sarcoma (KS)]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Thoracic Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Non-small cell lung cancer (NSCLC) without driver alterations'''
|-
|style="background-color:#eff3ff"|[[Non-small cell lung cancer |NSCLC, NOS]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, nonsquamous|Nonsquamous NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, squamous|Squamous NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, PD-L1-positive|PD-L1-positive NSCLC]]
|-
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_CNS_metastases|CNS metastases]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''NSCLC with driver alterations'''
|-
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_ALK-positive|ALK-positive NSCLC]]
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_BRAF-mutated|BRAF-mutated NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, c-Met-positive|c-Met-positive NSCLC]]
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_EGFR-mutated|EGFR-mutated NSCLC]]
|-
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_HER2-mutated|HER2-mutated NSCLC]]
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_KRAS-mutated|KRAS-mutated NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, MET-mutated|MET-mutated NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, NRG1-positive|NRG1-positive NSCLC]]
|-
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, RET-positive|RET-positive NSCLC]]
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_ROS1-positive|ROS1-positive NSCLC]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Other thoracic cancer'''
|-
|style="background-color:#eff3ff"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]]
|style="background-color:#eff3ff"|[[Small cell lung cancer |Small cell lung cancer (SCLC)]]
|style="background-color:#eff3ff"|[[Thymoma]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Site-agnostic'''
|-
|style="background-color:#eff3ff"|[[BRAF]]
|style="background-color:#eff3ff"|[[EGFR]]
|style="background-color:#eff3ff"|[[ERBB2 (HER2)]]
|style="background-color:#eff3ff"|[[ERBB3 (HER3)]]
|-
|style="background-color:#eff3ff"|[[MSI-H or dMMR]]
|style="background-color:#eff3ff"|[[NTRK]]
|style="background-color:#eff3ff"|[[RET]]
|style="background-color:#eff3ff"|[[SMO or PTCH-1 (Hedgehog)]]
|-
|style="background-color:#eff3ff"|[[TMB-H]]
|style="background-color:#eff3ff"|[[Carcinoma of unknown primary|Carcinoma of unknown primary (CUP)]]
|-
|}
<span id="malignantheme"></span>
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#cf0001"| '''Malignant Hematology'''
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Acute leukemias'''
|-
|style="width: 25%; background-color:#fee0d2"|[[Acute leukemia, KMT2A-rearranged]]
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, FLT3-positive | AML, FLT3-positive]]
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, IDH-mutated | AML, IDH-mutated]]
|-
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, NPM1-mutated | AML, NPM1-mutated]]
|style="width: 25%; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia, Ph-positive | B-ALL, Ph+]]
|-
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (T-ALL)]]
|style="background-color:#fee0d2"|[[Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm (BPDCN)]]
|style="background-color:#fee0d2"|[[CNS leukemia]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
|-
|style="background-color:#fee0d2"|[[Chronic myeloid leukemia | Chronic myeloid leukemia (CML)]]
|style="background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
|style="background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
|style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
|-
|style="background-color:#fee0d2"|[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]]
|style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis (PMF/SMF)]]
|style="background-color:#fee0d2"|[[Myeloproliferative neoplasm, accelerated phase|Myeloproliferative neoplasm, accelerated phase (MPN-AP)]] <span style="color: red"><small>New</small></span>
|style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]]
|-
|style="background-color:#fee0d2"|[[Systemic mastocytosis]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Aggressive lymphomas'''
|-
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
|style="background-color:#fee0d2"|[[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]]
|style="background-color:#fee0d2"|[[CNS lymphoma]]
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
|-
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma, gastric|Gastric DLBCL]] <span style="color: red"><small>New</small></span>
|style="background-color:#fee0d2"|[[High-grade B-cell lymphoma|High-grade B-cell lymphoma (HGBL)]]
|style="background-color:#fee0d2"|[[HIV-associated lymphoma]]
|style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
|-
|style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
|style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
|style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Indolent lymphomas'''
|-
|style="background-color:#fee0d2"|[[Chronic lymphocytic leukemia| Chronic lymphocytic leukemia (CLL/SLL)]]
|style="background-color:#fee0d2"|[[Follicular lymphoma|Follicular lymphoma (FL)]]
|style="background-color:#fee0d2"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]]
|style="background-color:#fee0d2"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]]
|-
|style="background-color:#fee0d2"|[[Indolent lymphoma|Indolent lymphoma (iNHL)]]
|style="background-color:#fee0d2"|[[B-cell lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]]
|style="background-color:#fee0d2"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]]
|style="background-color:#fee0d2"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Plasma cell dyscrasias'''
|-
|style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
|style="background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (main page)]]
|style="background-color:#fee0d2"|[[Multiple_myeloma,_induction|MM,]] induction
|style="background-color:#fee0d2"|[[Multiple_myeloma,_consolidation_and_maintenance|MM, consolidation &]] maintenance
|-
|style="background-color:#fee0d2"|[[Multiple_myeloma,_relapsed-refractory|MM, relapsed/refractory]]
|style="background-color:#fee0d2"|[[Plasma cell leukemia|Plasma cell leukemia (PCL)]]
|style="background-color:#fee0d2"|[[POEMS syndrome]]
|style="background-color:#fee0d2"|[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''T-cell and NK-cell neoplasms'''
|-
|style="background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
|style="background-color:#fee0d2"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]]
|style="background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
|style="background-color:#fee0d2"|[[Extranodal NK- and T-cell lymphoma, nasal type|Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT]]
|-
|style="background-color:#fee0d2"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]]
|style="background-color:#fee0d2"|[[NK- and T-cell lymphoma|NK- and T-cell lymphoma (NKTCL)]]
|style="background-color:#fee0d2"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]]
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic lymphoma (T-LBL)]]
|-
|style="background-color:#fee0d2"|[[T-cell prolymphocytic leukemia | T-cell prolymphocytic lymphoma (T-PLL)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Lymphoproliferative disorders'''
|-
|colspan="2" style="background-color:#fee0d2"|[[Castleman disease]]
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocytic disorders'''
|-
|style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]]
|style="background-color:#fee0d2"|[[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]]
|style="background-color:#fee0d2"|[[Langerhans cell histiocytosis|Langerhans cell histiocytosis (LCH)]]
|style="background-color:#fee0d2"|[[Rosai-Dorfman-Destombes disease]]
|-
|}
<span id="peds"></span>
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#ba871a"|'''Pediatric Neoplasms'''
|-
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric CNS malignancies'''
|-
|style="width: 25%; background-color:#e8d7b3"|[[Low-grade glioma, pediatric|Low-grade glioma]]
|style="width: 25%; background-color:#e8d7b3"|[[High-grade glioma, pediatric|High-grade glioma]]
|style="width: 25%; background-color:#e8d7b3"|[[Medulloblastoma]]
|style="width: 25%; background-color:#e8d7b3"|
|-
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric hematologic neoplasms'''
|-
|style="background-color:#e8d7b3"|[[B-cell acute lymphoblastic leukemia, pediatric | B-cell acute lymphoblastic leukemia (B-ALL)]]
|style="background-color:#e8d7b3"|[[B-cell acute lymphoblastic leukemia, pediatric, Ph-positive | B-ALL, Ph+]]
|style="background-color:#e8d7b3"|[[T-cell acute lymphoblastic leukemia, pediatric | T-cell acute lymphoblastic leukemia (T-ALL)]]
|style="background-color:#e8d7b3"|[[Acute myeloid leukemia, pediatric | Acute myeloid leukemia (AML)]]
|-
|style="background-color:#e8d7b3"|[[Anaplastic large cell lymphoma, pediatric | Anaplastic large cell lymphoma (ALCL)]]
|style="background-color:#e8d7b3"|[[Chronic myeloid leukemia, pediatric | Chronic myeloid leukemia (CML)]]
|style="background-color:#e8d7b3"|[[Juvenile myelomonocytic leukemia | Juvenile myelomonocytic leukemia (JMML)]]
|-
|style="background-color:#e8d7b3"|[[Classical Hodgkin lymphoma, pediatric |Classical Hodgkin lymphoma (cHL)]]
|style="background-color:#e8d7b3"|[[Non-Hodgkin lymphoma, pediatric | Non-Hodgkin lymphoma (NHL)]]
|-
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric solid tumors'''
|-
|style="background-color:#e8d7b3"|[[Epithelioid sarcoma]]
|style="background-color:#e8d7b3"|[[Ewing sarcoma, pediatric|Ewing sarcoma]]
|style="background-color:#e8d7b3"|[[Hepatoblastoma]]
|style="background-color:#e8d7b3"|[[Neuroblastoma]]
|-
|style="background-color:#e8d7b3"|[[Osteosarcoma, pediatric|Osteosarcoma]]
|style="background-color:#e8d7b3"|[[Retinoblastoma]]
|style="background-color:#e8d7b3"|[[Rhabdomyosarcoma, pediatric|Rhabdomyosarcoma]]
|style="background-color:#e8d7b3"|[[Wilms tumor]]
|-
|}
<span id="transplant"></span>
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#4a1486"|'''Transplant and Immune Effector Cells (IECs)'''
|-
|style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]]
|style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT]]
|style="width: 25%; background-color:#efedf5"|[[Autologous HSCT]]
|style="width: 25%; background-color:#efedf5"|[[Chimeric antigen receptor T cells (CAR-T)]]
|-
|style="background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]]
|style="background-color:#efedf5"|[[Hepatic veno-occlusive disease|Hepatic veno-occlusive disease (VOD/SOS)]]
|-
|}
<span id="classicalheme"></span>
 
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Classical Hematology'''
|-
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemostasis and thrombosis'''
|-
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]]
|style="width: 25%; background-color:#e5f5e0"|[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]]
|style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]]
|style="width: 25%; background-color:#e5f5e0"|[[Congenital thrombotic thrombocytopenic purpura|Congenital thrombotic thrombocytopenic purpura (cTTP)]]
|-
|style="width: 25%; background-color:#e5f5e0"|[[Hemophilia A]]
|style="width: 25%; background-color:#e5f5e0"|[[Hemophilia B]]
|style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]]
|style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]]
|-
|style="background-color:#e5f5e0"|[[Inherited thrombophilia]]
|style="background-color:#e5f5e0"|[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]]
|style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]]
|style="background-color:#e5f5e0"|[[Von Willebrand disease|von Willebrand disease (vWD)]]
|-
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Cytopenias'''
|-
|style="background-color:#e5f5e0"|[[Aplastic anemia]]
|style="background-color:#e5f5e0"|[[Autoimmune cytopenia]]
|style="background-color:#e5f5e0"|[[Immune thrombocytopenia|Immune thrombocytopenia (ITP)]]
|style="background-color:#e5f5e0"|[[Thrombocytopenia in liver disease]]
|-
|style="background-color:#e5f5e0"|[[WHIM syndrome]]
|-
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders and Hemoglobinopathies'''
|-
|style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]]
|style="background-color:#e5f5e0"|[[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]]
|style="background-color:#e5f5e0"|[[Cold agglutinin disease|Cold agglutinin disease (CAD)]]
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]
|-
|style="background-color:#e5f5e0"|[[Pyruvate kinase deficiency|Pyruvate kinase deficiency (PKD)]]
|style="background-color:#e5f5e0"|[[Beta thalassemia]]
|style="background-color:#e5f5e0"|[[Sickle cell disease|Sickle cell disease (SCD)]]
|-
|}
 
<div style="text-align:center"><big>'''[[Special:AllPages|Browse our complete index of pages]]'''</big></div>
 
==Additional Information==
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes [[how to contribute|continuous peer review]].
 
Any information that one feels would be helpful to other oncology providers is welcome. Visit [[how to contribute]] for more details.
 
Priorities of this project include:
<section begin=goals />
*'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]].
*'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature.
*'''[[:Category:Example chemotherapy order sets|Sample order sets]] and examples of supportive medications used with treatment regimens
*'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
*'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens.
<section end=goals />
 
Additional possibilities for this project may include:
*Creating synopses of pivotal clinical trials and regimens
*Prioritizing regimens by their efficacy and/or toxicity
*Capturing historical regimens that were standard-of-care prior to 2005
*Checklists for common clinical scenarios/diseases
*Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
 
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as [https://en.wikipedia.org/wiki/Main_Page Wikipedia], will significantly help ease-of-use and navigation.
 
<br><inputbox>
type=create
width=70
placeholder=Type the name of the page you want to create
break=no
</inputbox>

Revision as of 16:41, 16 November 2025


HemOnc.org - A Human-Curated Hematology/Oncology Reference

HemOnc.org is the largest freely available medical wiki of interventions, regimens, and general information relevant to the fields of hematology and oncology. Any healthcare professional can sign up to contribute; the accuracy and completeness of content is overseen by the Editorial Board. If this is your first time visiting, please start with the the tutorial page, review our philosophy, or just start exploring!
Regimens: 5,549 Guidelines: 1,173 Studies: 7,123 References: 10,098
Solid Tumors Malignant Hematology Pediatrics Transplant & IEC Classical Hematology

Solid Tumors
Breast Oncology
Early breast cancer (EBC)
EBC, NOS HR-positive EBC HER2-positive EBC HER2-low EBC
HR-positive and HER2-positive EBC Early triple-negative breast cancer (eTNBC)
Metastatic breast cancer (MBC)
MBC, NOS HR-positive MBC HER2-positive MBC HER2-low MBC
HR-positive and HER2-positive MBC Metastatic triple-negative breast cancer (mTNBC) CNS metastases
Breast cancer with molecular alterations
BRCA-mutated Breast cancer PI3K pathway-altered Breast cancer
Dermatologic Oncology
Melanoma
Melanoma, NOS BRAF-mutated Melanoma KIT-mutated Melanoma NRAS-mutated Melanoma
Uveal melanoma
Non-melanoma skin cancer (NMSC)
Cutaneous BCC Cutaneous SCC Merkel cell carcinoma (MCC)
Endocrine Oncology
Other endocrine cancers
Adrenocortical carcinoma Neuroendocrine tumor (NET) Neuroendocrine carcinoma (NEC) Pancreatic NET
Pheochromocytoma
Thyroid cancer without molecular alterations
Thyroid cancer, NOS Anaplastic thyroid cancer (ATC) Differentiated thyroid cancer (DTC) Medullary thyroid cancer (MTC)
Thyroid cancer with molecular alterations
BRAF-mutated Thyroid cancer RET-positive Thyroid cancer
Gastrointestinal Oncology
Upper GI tract
Esophageal cancer, NOS Esophageal adenocarcinoma Esophageal squamous cell carcinoma (ESCC) Gastric cancer, NOS
HER2-positive gastric cancer
Lower GI tract
Anal cancer Appendiceal tumor Colon cancer, NOS RAS wild-type colon cancer
Colorectal cancer (CRC), NOS BRAF-mutated CRC HER2-positive CRC MSI-H or dMMR CRC
RAS wild-type CRC Rectal cancer Small bowel adenocarcinoma
Hepatobiliary cancer
Biliary tract cancer Cholangiocarcinoma Gallbladder cancer Hepatocellular carcinoma (HCC)
Periampullary adenocarcinoma
Pancreatic cancer
Pancreatic adenocarcinoma, NOS BRCA-mutated Pancreatic adenocarcinoma NRG1-positive Pancreatic adenocarcinoma Pancreatic NET
Genitourinary Oncology
Kidney cancer
Renal cell carcinoma (RCC), NOS Clear cell RCC (ccRCC) Non-clear cell RCC (nccRCC) Papillary RCC
Sarcomatoid RCC VHL-associated RCC
Male genital tract
Penile cancer Prostate cancer, NOS Prostate cancer, HRD-positive Testicular cancer
Urinary tract cancer
Urothelial carcinoma, NOS Bladder cancer Upper tract urothelial carcinoma (UTUC)
Gynecologic Oncology
Ovarian cancer
High-grade serous ovarian cancer (HGSOC) Low-grade serous ovarian cancer (LGSOC) Ovarian cancer, BRCA-mutated
Other gynecologic cancer
Cervical cancer Endometrial cancer Gestational trophoblastic neoplasia Vulvar cancer
Head & Neck Oncology
Head and neck cancer Nasopharyngeal carcinoma (NPC) HPV+ Oropharyngeal cancer
Mesothelioma
Malignant peritoneal mesothelioma (MPEM) Malignant pleural mesothelioma (MPM)
Neuro-Oncology
Primary central nervous system (CNS) malignancies
Anaplastic glioma Craniopharyngioma Diffuse midline glioma New Glioblastoma (GBM)
Low-grade glioma Meningioma Subependymal giant cell astrocytoma (SEGA)
Secondary CNS malignancies
CNS carcinoma CNS leukemia CNS lymphoma CNS melanoma
Sarcoma
Bone sarcoma
Bone sarcoma, NOS Ewing sarcoma Giant-cell tumor of bone Osteosarcoma
Soft tissue sarcoma
Soft tissue sarcoma (STS), NOS Alveolar soft part sarcoma (ASPS) Dermatofibrosarcoma protuberans Desmoid tumor
Epithelioid sarcoma Gastrointestinal stromal tumor (GIST) Inflammatory myofibroblastic tumor (IMT) Leiomyosarcoma (LMS)
Liposarcoma PEComa Rhabdomyosarcoma (RMS) Tenosynovial giant cell tumor (TGCT)
Vascular sarcoma
Vascular sarcoma, NOS Angiosarcoma Kaposi sarcoma (KS)
Thoracic Oncology
Non-small cell lung cancer (NSCLC) without driver alterations
NSCLC, NOS Nonsquamous NSCLC Squamous NSCLC PD-L1-positive NSCLC
CNS metastases
NSCLC with driver alterations
ALK-positive NSCLC BRAF-mutated NSCLC c-Met-positive NSCLC EGFR-mutated NSCLC
HER2-mutated NSCLC KRAS-mutated NSCLC MET-mutated NSCLC NRG1-positive NSCLC
RET-positive NSCLC ROS1-positive NSCLC
Other thoracic cancer
Malignant pleural mesothelioma (MPM) Small cell lung cancer (SCLC) Thymoma
Site-agnostic
BRAF EGFR ERBB2 (HER2) ERBB3 (HER3)
MSI-H or dMMR NTRK RET SMO or PTCH-1 (Hedgehog)
TMB-H Carcinoma of unknown primary (CUP)

Malignant Hematology
Acute leukemias
Acute leukemia, KMT2A-rearranged Acute myeloid leukemia (AML) AML, FLT3-positive AML, IDH-mutated
AML, NPM1-mutated Acute promyelocytic leukemia (APL) B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+
T-cell acute lymphoblastic leukemia (T-ALL) Blastic plasmacytoid dendritic cell neoplasm (BPDCN) CNS leukemia
Myeloproliferative neoplasms and myelodysplastic syndromes
Chronic myeloid leukemia (CML) Chronic myelomonocytic leukemia (CMML) Essential thrombocythemia (ET) Hypereosinophilic syndrome (HES)
Myelodysplastic syndrome (MDS) Primary & secondary myelofibrosis (PMF/SMF) Myeloproliferative neoplasm, accelerated phase (MPN-AP) New Polycythemia vera (PV)
Systemic mastocytosis
Aggressive lymphomas
Burkitt lymphoma (BL) or Burkitt-like lymphoma Classical Hodgkin lymphoma (cHL) CNS lymphoma Diffuse large B-cell lymphoma (DLBCL)
Gastric DLBCL New High-grade B-cell lymphoma (HGBL) HIV-associated lymphoma Mantle cell lymphoma (MCL)
Mediastinal gray-zone lymphoma (MGZL) Primary mediastinal B-cell lymphoma (PMBL) Transformed lymphoma (TL)
Indolent lymphomas
Chronic lymphocytic leukemia (CLL/SLL) Follicular lymphoma (FL) Hairy cell leukemia (HCL) Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)
Indolent lymphoma (iNHL) MALT lymphoma Marginal zone lymphoma (MZL) Waldenström macroglobulinemia (WM/LPL)
Plasma cell dyscrasias
Light-chain (AL) amyloidosis Multiple myeloma (main page) MM, induction MM, consolidation & maintenance
MM, relapsed/refractory Plasma cell leukemia (PCL) POEMS syndrome Smoldering multiple myeloma (SMM)
T-cell and NK-cell neoplasms
Adult T-cell leukemia-lymphoma (ATLL) Anaplastic large cell lymphoma (ALCL) Cutaneous T-cell lymphoma (CTCL) Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT
Large granular lymphocytic (LGL) leukemia NK- and T-cell lymphoma (NKTCL) Peripheral T-cell Lymphoma (PTCL) T-cell acute lymphoblastic lymphoma (T-LBL)
T-cell prolymphocytic lymphoma (T-PLL)
Lymphoproliferative disorders
Castleman disease Post-transplant lymphoproliferative disorder (PTLD)
Histiocytic disorders
Erdheim-Chester disease (ECD) Hemophagocytic lymphohistiocytosis (HLH) Langerhans cell histiocytosis (LCH) Rosai-Dorfman-Destombes disease

Pediatric Neoplasms
Pediatric CNS malignancies
Low-grade glioma High-grade glioma Medulloblastoma
Pediatric hematologic neoplasms
B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+ T-cell acute lymphoblastic leukemia (T-ALL) Acute myeloid leukemia (AML)
Anaplastic large cell lymphoma (ALCL) Chronic myeloid leukemia (CML) Juvenile myelomonocytic leukemia (JMML)
Classical Hodgkin lymphoma (cHL) Non-Hodgkin lymphoma (NHL)
Pediatric solid tumors
Epithelioid sarcoma Ewing sarcoma Hepatoblastoma Neuroblastoma
Osteosarcoma Retinoblastoma Rhabdomyosarcoma Wilms tumor

Transplant and Immune Effector Cells (IECs)
Stem cell mobilization Allogeneic HSCT Autologous HSCT Chimeric antigen receptor T cells (CAR-T)
Graft versus host disease (GVHD) Hepatic veno-occlusive disease (VOD/SOS)

Classical Hematology
Hemostasis and thrombosis
Acquired coagulopathy Acquired thrombotic thrombocytopenic purpura (aTTP) Antiphospholipid antibody syndrome (APLAS) Congenital thrombotic thrombocytopenic purpura (cTTP)
Hemophilia A Hemophilia B Heparin-induced thrombocytopenia (HIT) Hereditary hemorrhagic telangiectasia (HHT)
Inherited thrombophilia Thrombotic microangiopathy (TMA) Venous thromboembolism (VTE) von Willebrand disease (vWD)
Cytopenias
Aplastic anemia Autoimmune cytopenia Immune thrombocytopenia (ITP) Thrombocytopenia in liver disease
WHIM syndrome
Hemolytic disorders and Hemoglobinopathies
Atypical hemolytic uremic syndrome (aHUS) Warm autoimmune hemolytic anemia (WAIHA) Cold agglutinin disease (CAD) Paroxysmal nocturnal hemoglobinuria (PNH)
Pyruvate kinase deficiency (PKD) Beta thalassemia Sickle cell disease (SCD)

Additional Information

Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes continuous peer review.

Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.

Priorities of this project include: <section begin=goals />

<section end=goals />

Additional possibilities for this project may include:

  • Creating synopses of pivotal clinical trials and regimens
  • Prioritizing regimens by their efficacy and/or toxicity
  • Capturing historical regimens that were standard-of-care prior to 2005
  • Checklists for common clinical scenarios/diseases
  • Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects

The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.


<inputbox> type=create width=70 placeholder=Type the name of the page you want to create break=no </inputbox>

Retrieved from "https://neoplasm.org/index.php?title=Main_Page&oldid=2"